CANbridge Completes Biomarker Study of Cancer Drug; Gains Taiwan Rights

CANbridge Life Sciences, a Beijing biopharma, successfully completed a biomarker study of CD95 ligand expression in patients with brain cancer, triggering a CANbridge milestone payment to Germany's Apogenix. In July 2015, CANbridge in-licensed China rights from Apogenix to APG101, a brain cancer treatment. APG101 targets the CD95 ligand to restore immune system function. In addition, CANbridge acquired Taiwan rights to the drug, where the biomarker test took place. CANbridge originally in-licensed rights to the drug in mainland China, South Korea and Macau. More details.... Share this with colleagues: // //